MentalHealthDaily

Alpha-Synuclein SAA Predicts Parkinson’s Levodopa Response Durability

by GLOOM

Photoreal illustration of CSF biomarker testing alongside dopaminergic neuron pathways, representing PD biomarker stratification.

A 2026 PPMI analysis found that Parkinson’s patients with positive CSF α-synuclein seed amplification assay results kept gaining levodopa benefit over follow-up, while SAA-negative patients showed faster ON-medication motor progression than SAA-positive patients: 0.87 vs. 3.47 MDS-UPDRS Part III points/year in 183 matched SAA-positive and 40 SAA-negative patients.1 Research Highlights ON-state progression split sharply: SAA-positive …

Sinemet (Carbidopa-Levodopa) Side Effects & Adverse Reactions (List)

by GLOOM

Sinemet is a pharmaceutical drug engineered by Merck that combines Carbidopa (a peripheral enzymatic inhibitor of DOPA decarboxylase) and Levodopa (an agent that crosses the blood-brain barrier to increase central concentrations of dopamine); hence it is frequently referred to as “Carbidopa-Levodopa.” The drug was initially approved by the U.S. FDA in 1988 for the treatment …